Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TWST.

← Back to Free Index

TWST

Analysis as of: 2026-08-14

Twist Bioscience Corporation

Twist Bioscience manufactures synthetic DNA products and related workflow tools, including genes, next-generation sequencing products, and antibody discovery solutions for research, diagnostics and therapeutics customers.

ai automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Better Biology Demand, Harder Value Capture

AI should create more biological designs to build, and the company owns a scaled manufacturing platform that can benefit. The key debate is whether that extra volume becomes durable, higher-quality economics rather than a premium-priced but still transactional tools story.

Analysis

Thesis

AI should expand the number of biological designs that must be physically built, and Twist’s silicon-based DNA platform lets it sell more genes, NGS products and discovery inputs into that loop. The 5-year upside depends on converting higher throughput into trusted, stickier and more profitable revenue; the stock outcome is tempered because the valuation already prices in much of that turnaround.

Last Economy Alignment

Twist benefits as AI makes biology design cheaper and increases build volume, and its low software commoditization exposure helps. But it still captures value mainly through product margin, so pricing can compress if DNA ordering becomes more catalog-like.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

1.8x (from 5 most recent analyses)

Reasoning

Twist can plausibly more than double revenue by 2031 through higher DNA synthesis throughput, NGS expansion, OEM mix, and AI-enabled discovery demand. The stock likely compounds much less than revenue because today’s premium valuation already embeds a large part of the operating turnaround. My multiple assumes profitability credibility improves and a premium over standard tools peers remains, but that Twist is still valued more like a specialized life-science tools company than a software platform.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether AI creates more biology demand; it likely does. The real risk is value capture: Twist must turn more volume into durable margin, cash generation and stickier commercial structures before a premium valuation can compound further. Supplier fragility, financing optionality and elevated expectations keep the stock more fragile than the revenue story.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On August 3, 2026, Twist reported record 3QFY26 revenue of 118.4 and raised FY26 guidance to 456-457 while reiterating Q4 adjusted EBITDA breakeven.
3QFY26 gross margin reached 52.8% and approximately 369,000 genes shipped, strengthening the case that higher throughput is improving factory economics.
No new material operating disclosure or financing event appeared on the IR and SEC pages through August 14, 2026; the next major repricing surface remains FY26 close and the next earnings report.

Forecast update

The business has de-risked somewhat, but the stock has rerated faster than fundamentals, so more of the next leg now depends on execution rather than multiple expansion.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.48

AI should cause more sequences to be designed, and this company owns one of the factories that turns those designs into real DNA. That helps, but because it mainly sells manufactured inputs, it still has to prove that speed, quality and trust keep pricing from becoming commodity-like.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$105.30

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research